Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefan Unterecker

Showing results (31-40 of 78) with videos related to

Pageof 8
Sort By:
International Clinical Psychopharmacology|December 18, 2018
Analysis of smoking behavior on the pharmacokinetics of antidepressants and antipsychotics: evidence for the role of alternative pathways apart from CYP1A2Maike Scherf-Clavel, Lydia Samanski, Leif G Hommers, et al.
Pharmacopsychiatry|March 2, 2026
Serum Concentration-Dependent Inhibition of CYP2D6 by Bupropion and Doxepin: Implications for Venlafaxine and Risperidone MetabolismGeorgios N Zioris, Bodo Warrings, Jürgen Deckert, et al.
Journal of Clinical Psychopharmacology|April 6, 2018
Comedication of Valproic Acid Is Associated With Increased Metabolism of ClozapineLeif Hommers, Magdalena Scharl, Gudrun Hefner, et al.
Plos One|November 17, 2022
Reduced midbrain raphe echogenicity in patients with fibromyalgia syndromeNurcan Üçeyler, Mira Schließer, Dimitar Evdokimov, et al.
Therapeutic Drug Monitoring|July 9, 2026
Risperidone Serum Levels in Depression: Insights From a Retrospective Therapeutic Drug Monitoring StudyMelike Kucukkarapinar, Kohler Meike, Weber Heike, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|May 6, 2015
Melperone but not bisoprolol or metoprolol is a clinically relevant inhibitor of CYP2D6: evidence from a therapeutic drug monitoring surveyGudrun Hefner, Stefan Unterecker, Mohamed E E Shams, et al.
Pharmacopsychiatry|December 8, 2020
Dose-Corrected Serum Concentrations and Metabolite to Parent Compound Ratios of Venlafaxine and Risperidone from Childhood to Old AgeStefanie Fekete, Maike Scherf-Clavel, Manfred Gerlach, et al.
International Journal of Clinical Pharmacy|May 11, 2023
Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort studyMaike Scherf-Clavel, Amelie Frantz, Andreas Eckert, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|July 25, 2021
Patients with higher vitamin D levels show stronger improvement of self-reported depressive symptoms in psychogeriatric day-care settingLinda D Zech, Maike Scherf-Clavel, Christine Daniels, et al.
Journal of Psychopharmacology (Oxford, England)|July 17, 2020
Higher venlafaxine serum concentrations necessary for clinical improvement? Time to re-evaluate the therapeutic reference range of venlafaxineMaike Scherf-Clavel, Leif Hommers, Catherina Wurst, et al.
Pageof 8

Showing results (31-40 of 78) with videos related to

Sort By:
Pageof 8
International Clinical Psychopharmacology|December 18, 2018
Analysis of smoking behavior on the pharmacokinetics of antidepressants and antipsychotics: evidence for the role of alternative pathways apart from CYP1A2Maike Scherf-Clavel, Lydia Samanski, Leif G Hommers, et al.
Pharmacopsychiatry|March 2, 2026
Serum Concentration-Dependent Inhibition of CYP2D6 by Bupropion and Doxepin: Implications for Venlafaxine and Risperidone MetabolismGeorgios N Zioris, Bodo Warrings, Jürgen Deckert, et al.
Journal of Clinical Psychopharmacology|April 6, 2018
Comedication of Valproic Acid Is Associated With Increased Metabolism of ClozapineLeif Hommers, Magdalena Scharl, Gudrun Hefner, et al.
Plos One|November 17, 2022
Reduced midbrain raphe echogenicity in patients with fibromyalgia syndromeNurcan Üçeyler, Mira Schließer, Dimitar Evdokimov, et al.
Therapeutic Drug Monitoring|July 9, 2026
Risperidone Serum Levels in Depression: Insights From a Retrospective Therapeutic Drug Monitoring StudyMelike Kucukkarapinar, Kohler Meike, Weber Heike, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|May 6, 2015
Melperone but not bisoprolol or metoprolol is a clinically relevant inhibitor of CYP2D6: evidence from a therapeutic drug monitoring surveyGudrun Hefner, Stefan Unterecker, Mohamed E E Shams, et al.
Pharmacopsychiatry|December 8, 2020
Dose-Corrected Serum Concentrations and Metabolite to Parent Compound Ratios of Venlafaxine and Risperidone from Childhood to Old AgeStefanie Fekete, Maike Scherf-Clavel, Manfred Gerlach, et al.
International Journal of Clinical Pharmacy|May 11, 2023
Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort studyMaike Scherf-Clavel, Amelie Frantz, Andreas Eckert, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|July 25, 2021
Patients with higher vitamin D levels show stronger improvement of self-reported depressive symptoms in psychogeriatric day-care settingLinda D Zech, Maike Scherf-Clavel, Christine Daniels, et al.
Journal of Psychopharmacology (Oxford, England)|July 17, 2020
Higher venlafaxine serum concentrations necessary for clinical improvement? Time to re-evaluate the therapeutic reference range of venlafaxineMaike Scherf-Clavel, Leif Hommers, Catherina Wurst, et al.
Pageof 8